WO2004105780A3 - Compositions comprising gastrin compounds and their use in diabetes - Google Patents

Compositions comprising gastrin compounds and their use in diabetes Download PDF

Info

Publication number
WO2004105780A3
WO2004105780A3 PCT/CA2004/000769 CA2004000769W WO2004105780A3 WO 2004105780 A3 WO2004105780 A3 WO 2004105780A3 CA 2004000769 W CA2004000769 W CA 2004000769W WO 2004105780 A3 WO2004105780 A3 WO 2004105780A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diabetes
gastrin compounds
beneficial effects
gastrin
Prior art date
Application number
PCT/CA2004/000769
Other languages
French (fr)
Other versions
WO2004105780A2 (en
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Antonio Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/016660 external-priority patent/WO2003100024A2/en
Priority to MXPA05012605A priority Critical patent/MXPA05012605A/en
Priority to AU2004243541A priority patent/AU2004243541A1/en
Priority to BRPI0410710-1A priority patent/BRPI0410710A/en
Priority to EP04737749A priority patent/EP1648495A2/en
Priority to JP2006529497A priority patent/JP2007513059A/en
Application filed by Waratah Pharmaceuticals Inc, Antonio Cruz filed Critical Waratah Pharmaceuticals Inc
Priority to CA002527186A priority patent/CA2527186A1/en
Priority to US10/558,523 priority patent/US20080039379A1/en
Publication of WO2004105780A2 publication Critical patent/WO2004105780A2/en
Publication of WO2004105780A3 publication Critical patent/WO2004105780A3/en
Priority to IL171902A priority patent/IL171902A0/en
Priority to NO20055582A priority patent/NO20055582L/en
Priority to US12/269,451 priority patent/US20090156494A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes.
PCT/CA2004/000769 2002-05-24 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes WO2004105780A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/558,523 US20080039379A1 (en) 2003-05-27 2004-05-27 Compositions Comprising Gastrin Compounds and Their Use in Diabetes
AU2004243541A AU2004243541A1 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes
BRPI0410710-1A BRPI0410710A (en) 2003-05-27 2004-05-27 compositions and methods comprising gastrin compounds and their uses
EP04737749A EP1648495A2 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes
JP2006529497A JP2007513059A (en) 2003-05-27 2004-05-27 Compositions containing gastrin compounds and their use in diabetes
MXPA05012605A MXPA05012605A (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes.
CA002527186A CA2527186A1 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes
IL171902A IL171902A0 (en) 2002-05-24 2005-11-10 Compositions comprising gastrin compounds and their use in diabetes
NO20055582A NO20055582L (en) 2003-05-27 2005-11-25 Compositions and Methods comprising Gastrin Compounds
US12/269,451 US20090156494A1 (en) 2003-05-27 2008-11-12 Compositions and methods comprising gastrin compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US03/16660 2003-05-27
PCT/US2003/016660 WO2003100024A2 (en) 2002-05-24 2003-05-27 Treatment for diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/269,451 Continuation US20090156494A1 (en) 2003-05-27 2008-11-12 Compositions and methods comprising gastrin compounds

Publications (2)

Publication Number Publication Date
WO2004105780A2 WO2004105780A2 (en) 2004-12-09
WO2004105780A3 true WO2004105780A3 (en) 2005-01-20

Family

ID=33488788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000769 WO2004105780A2 (en) 2002-05-24 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes

Country Status (11)

Country Link
EP (1) EP1648495A2 (en)
JP (1) JP2007513059A (en)
CN (1) CN1829528A (en)
AU (1) AU2004243541A1 (en)
BR (1) BRPI0410710A (en)
CA (1) CA2527186A1 (en)
MX (1) MXPA05012605A (en)
NO (1) NO20055582L (en)
PL (1) PL379145A1 (en)
RU (1) RU2005140518A (en)
WO (1) WO2004105780A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992060B2 (en) 2001-01-12 2006-01-31 Waratah Pharmaceuticals, Inc. Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
ATE445407T1 (en) 2002-06-07 2009-10-15 Waratah Pharmaceuticals Inc METHODS AND COMPOSITIONS TO TREAT DIABETES
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
RU2006131046A (en) * 2004-01-30 2008-03-10 Уэрейта Фармасьютикалз, Инк. (Ca) JOINT USE OF GLP-1 AGONIST AND GASTRIN COMPOUNDS
US20100256061A1 (en) * 2007-03-02 2010-10-07 Antonio Cruz Gastrin compound for diabetes treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044400A1 (en) * 1999-01-29 2000-08-03 Waratah Pharmaceuticals, Inc. Treatment for diabetes
WO2002055152A2 (en) * 2001-01-12 2002-07-18 Waratah Pharmaceuticals, Inc. Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
WO2004037195A2 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1842552A1 (en) * 1994-01-24 2007-10-10 The General Hospital Corporation Treatment for diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044400A1 (en) * 1999-01-29 2000-08-03 Waratah Pharmaceuticals, Inc. Treatment for diabetes
WO2002055152A2 (en) * 2001-01-12 2002-07-18 Waratah Pharmaceuticals, Inc. Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
WO2004037195A2 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes

Also Published As

Publication number Publication date
RU2005140518A (en) 2007-07-10
BRPI0410710A (en) 2006-06-13
NO20055582L (en) 2006-02-27
PL379145A1 (en) 2006-07-24
AU2004243541A1 (en) 2004-12-09
WO2004105780A2 (en) 2004-12-09
CA2527186A1 (en) 2004-12-09
CN1829528A (en) 2006-09-06
EP1648495A2 (en) 2006-04-26
MXPA05012605A (en) 2006-02-22
JP2007513059A (en) 2007-05-24
NO20055582D0 (en) 2005-11-25

Similar Documents

Publication Publication Date Title
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003270015A1 (en) Compounds, compositions, and methods
AU2003299034A1 (en) Transdermal compositions
HK1070656A1 (en) Compounds, compositions, and methods
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
AU2003299612A1 (en) Compounds, compositions and methods
AU2003218767A1 (en) Fabric treatment composition
IL167936A0 (en) Compounds, compositions,and methods
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
IL175369A0 (en) Novel compound, corresponding compositions, preparation and/or treatment methods
AU2003290507A1 (en) Compounds, compositions and methods
AU2003277079A1 (en) Compounds, compositions, and methods
NO20055582L (en) Compositions and Methods comprising Gastrin Compounds
AU2003303955A1 (en) Sporicidal composition
EP1576083B8 (en) Laundry treatment compositions
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
AU2003300031A1 (en) Compounds, compositions, and methods
AU2003267169A1 (en) Compounds, compositions and methods
EP1593684A4 (en) Caprazene as novel compound and derivatives thereof, and caprazol as novel compound and derivatives thereof
WO2004056762A3 (en) Novel aminobenzophenone compounds
WO2005082873A3 (en) 1,4-benzothiazepans and derivatives thereof
WO2005048715A3 (en) Organophosphoric compounds and use thereof
ZA200409130B (en) Compounds, compositions, and methods.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022042.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171902

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004243541

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200509276

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012605

Country of ref document: MX

Ref document number: 2006529497

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2527186

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057022612

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004243541

Country of ref document: AU

Date of ref document: 20040527

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004243541

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004737749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2658/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005140518

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057022612

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004737749

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410710

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10558523

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10558523

Country of ref document: US